NASDAQ: IRDOpus Genetics Inc Stock
$4.08+0.00 (+0%)
Updated Jun 23, 2026
IRD Price
$4.08
Fair Value Price
-$0.27
Market Cap
$332.09M
52 Week Low
$0.90
52 Week High
$5.81
P/E
-3.07x
P/B
-7.25x
P/S
32.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.98M
Earnings
-$106.93M
Gross Margin
100%
Operating Margin
-890.71%
Profit Margin
-892.4%
Debt to Equity
-1.92
Operating Cash Flow
-$39M
Beta
0.99
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IRD Overview
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IRD's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IRD
Ranked#421 of 467
Ranked#421 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.25 | A | |
| $51.34 | A | |
| $2.17 | A |
Be the first to know about important IRD news, forecast changes, insider trades & much more!
IRD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IRD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IRD ($4.08) is overvalued by 1,593.5% relative to our estimate of its Fair Value price of -$0.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IRD ($4.08) is not significantly undervalued (1,593.5%) relative to our estimate of its Fair Value price of -$0.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IRD due diligence checks available for Premium users.
Valuation
IRD fair value
Fair Value of IRD stock based on Discounted Cash Flow (DCF)
Price
$4.08
Fair Value
-$0.27
Undervalued by
1,593.50%
IRD ($4.08) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IRD ($4.08) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IRD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.07x
Industry
15.59x
Market
7.68x
IRD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-7.25x
Industry
5.15x
IRD's financial health
Profit margin
Revenue
$2.2M
Net Income
-$65.5M
Profit Margin
-3,038.2%
IRD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IRD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$66.8M
Liabilities
$87.9M
Debt to equity
-1.92
IRD's short-term assets ($66.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRD's long-term liabilities ($78.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IRD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.7M
Investing
$0.0
Financing
$27.6M
IRD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IRD vs Biotech Stocks
Opus Genetics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.